CEL-SCI patent for LEAPS Vaccine Platform Technology approved

U.S Patent and Trademark Office permits a patent titled  “Method for Inducing an Immune Response and Formulations Thereof” for CEL-SCI Corporation’s LEAPS Vaccine Platform technology. CEL-SCI’s patented invention relates to methods of diagnosing, preventing, and treating disease. LEAPS Vaccine Platform technology is a patented, T-cell modulation, peptide epitope delivery technology that enables CEL-SCI to design and synthesize proprietary peptide immunogens. LEAPS compounds consist of a small T-cell binding peptide ligand linked with a disease-associated peptide antigen.

Invention methods are addressed for diagnosing,  preventing and treating infectious diseases, including using cellular delivery approaches, with indications such as influenza, including swine and avian flu, other viruses such as herpes, and also bacteria and parasites. The LEAPS platform technology is currently being developed as a therapeutic vaccine for rheumatoid arthritis (RA) under a $1.5 million grant from the U.S. National Institutes of Health (NIH).

Dr. Daniel Zimmerman, Senior Vice President of Research, Cellular Immunology said “As we move the first LEAPS platform vaccine candidate towards potential human studies, we are pleased by this important extra step forward. This patent expands and fortifies the intellectual property protection for our LEAPS technology platform.”